AcquisitionOther
CATALYST PHARMACEUTICALS, INC. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
CATALYST PHARMACEUTICALS, INC. -> target · $160 million
Rights to FYCOMPA® (Perampanel) CIII Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience Expected to be Accretive in 2023 CORAL GABLES, Fla., Jan.
Open source record (SEC) ↗